Top Tech Companies (32)
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues. We have secured the exclusive worldwide...
Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.
SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a...
Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design...
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid...
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio...
WEX Pharmaceuticals Inc. is a late-stage drug development company in Vancouver, Canada dedicated to the research, development, manufacture, and commercialization of Halneuron®, a new novel non-opioid analgesic. Halneuron® is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology: - Non-addictive, no withdrawal symptoms and no euphoria - No build of up of tolerance over time - A long duration of...
Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.
Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance...
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
